Nektar Therapeutics
NASDAQ:NKTRBiotechnology
-$1.24 today
- Market cap
- $987.44M
- Beta
- 1.15
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$6.39
Volume 0.71M
Average 1.00M
NKTR Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Nektar TherapeuticsNASDAQ: NKTR
Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026
Net change in cash turns negative
Q2 FY2026 net change in cash was -$110.31M, compared with $4.09M a year earlier. Trailing-twelve-month net change in cash was $15.21M.
Context
- Net change in cash amounted to 52.8% of revenue in FY2025, up 43.6 pp from a year earlier.
- Net change in cash increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly net change in cash holds near -$110.31M or moves back toward the trailing-twelve-month quarterly average of $3.8M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (29.14M) USD
- Year-over-year change
- -424.6%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (29.14M) | -424.6% |
| FY2024 | 2024-12-31 | 8.98M | +116.9% |
| FY2023 | 2023-12-31 | (52.95M) | -184.0% |
| FY2022 | 2022-12-31 | 63.01M | +136.3% |
| FY2021 | 2021-12-31 | (173.74M) | — |
Net Change in Cash vs competitors
How NKTR compares with its peers on the latest reported figures
- Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1.2% is the 4th highest of 9, against a peer median of -75.2%.
- Net change in cash amounts to 27.9% of revenue for NKTR, versus a peer median of 83.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $98M USD | -206.5% | +7.5% | 83.8% | |
| LTM Mar 2026 | $79.05M USD | -221.2% | +105.0% | 50.3% | |
| LTM Dec 2025 | $72.37M USD | — | +192.0% | 99.5% | |
| LTM Mar 2026 | €51.59M EUR | -57.3% | +106.7% | 138.3% | |
| LTM Jun 2024 | $37.95M USD | — | +20.2% | 584.8% | |
| LTM Mar 2026 | $35.1M USD | +1528.7% | -56.4% | — | |
| LTM Mar 2026 | $32.8M USD | +118.5% | -52.8% | 70.0% | |
| FY2025 | €30.44M EUR | +623.1% | +15.9% | 1092.1% | |
| LTM Mar 2026 | $24.17M USD | -93.2% | -52.2% | 6.3% | |
| LTM Jun 2026 | $15.21M USD | +1.2% | — | 27.9% | |
| LTM Jun 2026 | $126K USD | -99.1% | — | 0.1% | |
| Peer median (excluding NKTR) | — | -75.2% | +15.9% | 83.8% | |
Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (523.84M) | (368.2M) | (276.06M) | (118.96M) | (164.08M) |
| Depreciation & Amortization | 14.15M | 13.03M | 7.82M | 4.39M | (4.49M) |
| Deferred Income Tax | 8.02M | 2.71M | (140K) | 0 | 0 |
| Stock-Based Compensation | 94.67M | 57.32M | 33.39M | 21.61M | 12.65M |
| Change in Working Capital | (23.08M) | 492K | (19.8M) | (6.24M) | (37.02M) |
| Accounts Receivables | 12.4M | 16.51M | 4.78M | (3.05M) | 0 |
| Inventory | (509K) | (3.4M) | 699K | 497K | 0 |
| Accounts Payables | (11.69M) | 3.1M | (2.88M) | 2.67M | (625K) |
| Other Working Capital | (23.27M) | (15.72M) | (22.39M) | (6.36M) | (36.39M) |
| Other Non-Cash Items | 17.41M | (9.36M) | 62.19M | (76.51M) | (15.58M) |
| Operating Cash Flow | (412.66M) | (304.01M) | (192.61M) | (175.71M) | (208.51M) |
| Capital Expenditures | (14.99M) | (5.68M) | (865K) | (1.47M) | (171K) |
| Acquisitions (Net) | (217.77M) | 13.2M | 0 | 65.39M | (697K) |
| Purchases of Investments | (960.69M) | (467.91M) | (511.7M) | (261.71M) | (285.01M) |
| Sales of Investments | 1.18B | 826.23M | 650.88M | 340.36M | 284.68M |
| Other Investing Activities | 217.77M | 0 | 1.25M | 0 | 0 |
| Investing Cash Flow | 202.78M | 365.84M | 139.56M | 142.57M | (1.2M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 33.24M | 758K | 30K | 30.12M | 180.57M |
| Common Stock Repurchased | 0 | 0 | 0 | (3M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3M | 750K | 0 | 15M | 0 |
| Financing Cash Flow | 36.24M | 1.51M | 30K | 42.12M | 180.57M |
| Effect of Forex Changes | (92K) | (327K) | 62K | (4K) | 6K |
| Net Change in Cash | (173.74M) | 63.01M | (52.95M) | 8.98M | (29.14M) |
| Free Cash Flow | (427.65M) | (309.68M) | (193.47M) | (177.18M) | (208.68M) |
Nektar Therapeutics
NASDAQ:NKTR
Intrinsic Alpha fair value
Locked
Current Price
$34.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.